SPRB Stock Price, Spruce Biosciences Inc Quote, Chart

Market Summary

USD0.700.00

Market Closed

0.00%

SPRB Alerts

1 major insider sales recently.

SPRB Stock Price

View Fullscreen

SPRB RSI Chart

SPRB Valuation

Market Cap

28.8M

Price/Earnings (Trailing)

-0.6

Price/Sales (Trailing)

2.85

Price/Free Cashflow

-0.87

SPRB Price/Sales (Trailing)

SPRB Profitability

Return on Equity

-62.63%

Return on Assets

-46.1%

Free Cashflow Yield

-115.54%

SPRB Fundamentals

SPRB Revenue

Revenue (TTM)

10.1M

Rev. Growth (Yr)

162.01%

Rev. Growth (Qtr)

-6.64%

SPRB Earnings

Earnings (TTM)

-47.9M

Earnings Growth (Yr)

10.72%

Earnings Growth (Qtr)

19.46%

Breaking Down SPRB Revenue

Last 30 days

-5.4%

Last 90 days

-79.4%

Trailing 12 Months

-66.3%

How does SPRB drawdown profile look like?

SPRB Financial Health

Current Ratio

4.18

Debt/Equity

0.02

Debt/Cashflow

-19.38

SPRB Investor Care

Shares Dilution (1Y)

72.79%

Diluted EPS (TTM)

-1.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	3.5M	5.5M	8.3M	10.1M
2022	0	0	821.0K	1.5M
2021	0	0	0	119.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Spruce Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 21, 2024	novo holdings a/s	sold	-350,951	0.7547	-465,021	-
Mar 20, 2024	novo holdings a/s	sold	-264,081	0.7336	-359,979	-
Mar 19, 2024	novo holdings a/s	sold	-447,715	0.755	-593,000	-
Mar 18, 2024	novo holdings a/s	sold	-647,008	0.7684	-842,020	-
Mar 14, 2024	novo holdings a/s	sold	-1,698,900	0.8884	-1,912,320	-
Dec 29, 2023	charlton ralph william iii	acquired	9,150	0.9775	9,361	chief medical officer
Dec 29, 2023	gharib samir m.	acquired	11,001	0.9775	11,255	president & cfo
Dec 15, 2023	gharib samir m.	sold (taxes)	-59,917	1.66	-36,095	president & cfo
Dec 15, 2023	gharib samir m.	acquired	-	-	112,250	president & cfo
Dec 15, 2023	szwarcberg javier b.	acquired	-	-	111,000	chief executive officer

Which funds bought or sold SPRB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Rosalind Advisors, Inc.	reduced	-4.92	-3,462,660	1,185,470	1.11%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	22,000	22,000	-%
Apr 19, 2024	CALDWELL SUTTER CAPITAL, INC.	unchanged	-	-2,144	786	-%
Mar 11, 2024	VANGUARD GROUP INC	added	150	1,667,720	2,409,600	-%
Feb 14, 2024	Alyeska Investment Group, L.P.	reduced	-60.00	-1,088,000	1,172,000	0.01%
Feb 14, 2024	CITADEL ADVISORS LLC	added	44.26	147,575	317,143	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-7.71	4,000	26,000	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	56,950	249,050	-%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-8.82	60,639	393,666	-%

Are Funds Buying or Selling SPRB?

Are funds buying SPRB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SPRB

No. of Funds

SPRB Alerts

1 major insider sales recently.

Unveiling Spruce Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	rosalind advisors, inc.	3.67%	1,508,419	SC 13G/A
Mar 28, 2024	novo holdings a/s	3.9%	1,656,000	SC 13D/A
Mar 28, 2024	radoff bradley louis	6.9%	2,825,000	SC 13G
Mar 25, 2024	novo holdings a/s	6.4%	2,756,000	SC 13D/A
Mar 20, 2024	novo holdings a/s	10.9%	4,671,021	SC 13D/A
Mar 18, 2024	novo holdings a/s	15.1%	6,466,020	SC 13D/A
Mar 07, 2024	healthcap viii, l.p.	8.9%	3,685,621	SC 13D/A
Feb 14, 2024	armistice capital, llc	5.48%	2,230,000	SC 13G
Feb 14, 2024	rock springs capital management lp	6.41%	2,609,125	SC 13G/A
Feb 14, 2024	citadel advisors llc	0.2%	6	SC 13G/A

Recent SEC filings of Spruce Biosciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	SC 13G/A	Major Ownership Report
Apr 05, 2024	ARS	ARS
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	DEFA14A	DEFA14A
Mar 28, 2024	SC 13D/A	13D - Major Acquisition
Mar 28, 2024	SC 13G	Major Ownership Report
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	SC 13D/A	13D - Major Acquisition
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	SC 13D/A	13D - Major Acquisition

Peers (Alternatives to Spruce Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Spruce Biosciences Inc News

Latest updates

Spruce Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)								(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4	2021Q3
Revenue	-6.6%	2,869	3,073	2,165	2,000	1,095	266	154	41.00
Operating Expenses	-16.0%	14,051	16,731	16,137	15,163	12,111	11,557	9,135	11,400
S&GA Expenses	-8.8%	2,951	3,237	3,011	3,451	3,272	2,766	2,877	2,793
R&D Expenses	-17.7%	11,100	13,494	13,126	11,712	8,839	8,791	6,258	8,607
Interest Expenses	-10.9%	106	119	127	131	129	110	88.00	88.00
Net Income	19.5%	-9,950	-12,354	-12,824	-12,791	-11,144	-11,401	-9,184	-11,447
Net Income Margin	19.9%	-4.74*	-5.92*	-8.77*	-13.46*	-30.32*	-53.86*	-355.39*	-
Free Cashflow	8.7%	-11,209	-12,276	1,993	-11,790	-11,738	-8,580	-9,805	-7,662

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-8.0%	104	113	126	139	86.00	95.00	105	115	126	135	143	154	163	78.00	-
Current Assets	-8.1%	102	111	124	137	84.00	93.00	97.00	95.00	92.00	94.00	111	152	160	74.00	5.00
Cash Equivalents	-2.5%	96.00	99.00	97.00	74.00	24.00	22.00	47.00	23.00	43.00	58.00	78.00	149	157	72.00	4.00
Liabilities	-0.6%	27.00	28.00	29.00	31.00	17.00	17.00	15.00	15.00	15.00	15.00	13.00	13.00	13.00	14.00	8.00
Current Liabilities	1.1%	24.00	24.00	23.00	23.00	12.00	12.00	10.00	9.00	9.00	9.00	7.00	7.00	10.00	10.00	4.00
Long Term Debt	-18.7%	2.00	2.00	3.00	3.00	3.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	2.00	3.00	3.00
LT Debt, Current	0%	2.00	2.00	2.00	2.00	2.00	1.00	1.00	0.00	-	-	-	-	3.00	2.00	1.00
LT Debt, Non Current	-18.7%	2.00	2.00	3.00	3.00	3.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	2.00	3.00	3.00
Shareholder's Equity	-10.4%	77.00	85.00	97.00	108	68.00	78.00	89.00	100	111	120	130	141	149	-	-
Retained Earnings	-5.3%	-197	-187	-174	-162	-149	-138	-126	-114	-103	-93.90	-82.50	-70.73	-60.84	-52.50	-31.30
Additional Paid-In Capital	0.4%	274	273	272	270	218	218	217	216	215	214	213	211	210	1.00	1.00
Shares Outstanding	0.8%	41.00	41.00	41.00	40.00	24.00	24.00	23.00	23.00	23.00	23.00	23.00	23.00	-	-	-
Float	-	-	-	75.00	-	-	-	23.00	-	-	-	143	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	8.6%	-11,209	-12,269	1,993	-11,790	-11,738	-8,578	-9,541	-11,826	-9,799	-7,597	-9,694	-8,787	-9,266	-7,597	-4,700	-5,956	-	-
Share Based Compensation	8.8%	1,221	1,122	1,219	1,060	802	783	905	1,141	797	1,031	1,010	1,120	409	218	96.00	32.00	-	-
Cashflow From Investing	-33.5%	9,300	13,993	22,000	10,484	14,569	-16,893	33,507	-7,491	-5,983	-12,335	-60,831	-19.00	-24.00	-43.00	-	-	-	-
Cashflow From Financing	-36.3%	-552	-405	-432	50,529	36.00	-90.00	-99.00	-88.00	167	17.00	176	283	94,282	43,197	-99.00	43,655	-	-

SPRB Income Statement

2023-12-31

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Collaboration revenue	$ 10,089	$ 0
Operating expenses:
Research and development	49,432	35,198
General and administrative	12,650	12,085
Total operating expenses	62,082	47,283
Loss from operations	(51,993)	(47,283)
Interest expense	(483)	(420)
Interest and other income, net	4,557	1,523
Net loss	(47,919)	(46,180)
Other comprehensive gain (loss), net of tax:
Unrealized gain (loss) on available for sale securities	558	(374)
Total comprehensive loss	$ (47,361)	$ (46,554)
Net loss per share, basic	$ (1.24)	$ (1.96)
Net loss per share,diluted	$ (1.24)	$ (1.96)
Weighted-average shares of common stock outstanding, basic	38,510,220	23,527,116
Weighted-average shares of common stock outstanding,diluted	38,510,220	23,527,116

SPRB Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 96,339	$ 24,487
Short-term investments	0	54,590
Prepaid expenses	3,876	3,320
Other current assets	1,968	1,211
Total current assets	102,183	83,608
Right-of-use assets	1,181	1,400
Other assets	582	640
Total assets	103,946	85,648
Current liabilities:
Accounts payable	3,332	1,426
Accrued expenses and other current liabilities	14,600	9,399
Term loan, current portion	1,622	1,622
Deferred revenue	4,911	0
Total current liabilities	24,465	12,447
Lease liabilities, net of current portion	1,019	1,261
Term loan, net of current portion	1,717	3,293
Other liabilities	236	161
Total liabilities	27,437	17,162
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.0001 par value; 200,000,000 shares authorized as of December 31, 2023 and 2022; 41,029,832 and 23,601,004 shares issued and outstanding as of December 31, 2023 and 2022, respectively	4	3
Additional paid-in capital	273,737	218,354
Accumulated other comprehensive loss	0	(558)
Accumulated deficit	(197,232)	(149,313)
Total stockholders' equity	76,509	68,486
Total liabilities and stockholders' equity	$ 103,946	$ 85,648

About Spruce Biosciences Inc

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

CEO	Dr. Javier Szwarcberg M.D., M.P.H.
WEBSITE	sprucebiosciences.com
INDUSTRY	Biotechnology
EMPLOYEES	32

Spruce Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Spruce Biosciences Inc? What does SPRB stand for in stocks?

SPRB is the stock ticker symbol of Spruce Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Spruce Biosciences Inc (SPRB)?

As of Fri Apr 26 2024, market cap of Spruce Biosciences Inc is 28.8 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SPRB stock?

You can check SPRB's fair value in chart for subscribers.

What is the fair value of SPRB stock?

You can check SPRB's fair value in chart for subscribers. The fair value of Spruce Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Spruce Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SPRB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Spruce Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether SPRB is over valued or under valued. Whether Spruce Biosciences Inc is cheap or expensive depends on the assumptions which impact Spruce Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SPRB.

What is Spruce Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, SPRB's PE ratio (Price to Earnings) is -0.6 and Price to Sales (PS) ratio is 2.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SPRB PE ratio will change depending on the future growth rate expectations of investors.